We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 29

Intellectual Property Weekly Abstracts Bulletin Week of July 3, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • July 5 2017

Supreme Court of Canada invalidates the promise doctrine AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36 Drug: esomeprazole In this decision, the


Supreme Court of Canada invalidates the promise doctrine
  • Borden Ladner Gervais LLP
  • Canada
  • July 3 2017

In this decision, the Supreme Court of Canada (SCC) overturned the decision of the Federal Court of Appeal (FCA), and held the patent to be valid and


Supreme Court Updates - Intellectual Property Weekly Abstracts - Week of January 16, 2017
  • Borden Ladner Gervais LLP
  • Canada
  • January 18 2017

The Supreme Court of Canada announced that judgment in this application for leave to appeal will be delivered on Thursday, January 19, 2017. The


Class action certification against Pfizer for an allegation of unlawful abuse of the patent system is overturned
  • Borden Ladner Gervais LLP
  • Canada
  • December 17 2015

The British Columbia Court of Appeal has overturned the certification of a class action relating to the drug Viagra, dismissing the action. The


Ramipril section 8 appeal dismissed from the bench by the Supreme Court of Canada
  • Borden Ladner Gervais LLP
  • Canada
  • April 22 2015

On Monday, April 20, 2015, the Supreme Court of Canada heard the appeal of 2014 FCA 68, relating to the issue of damages under section 8 of the


Intellectual property weekly abstracts bulletin
  • Borden Ladner Gervais LLP
  • Canada
  • July 29 2013

The Federal Court of Appeal has set aside the judgment of the Federal Court, and found that Canadian Patent No. 1,366,777 is valid, and infringed by


Court of Appeal considers comity as it applies to NOC proceedings
  • Borden Ladner Gervais LLP
  • Canada
  • December 4 2012

Apotex v.


Leave for appeal dismissed with costs
  • Borden Ladner Gervais LLP
  • Canada
  • December 4 2012

The Supreme Court of Canada dismissed Wyeth’s application for leave to appeal the decision of the Federal Court of Appeal which permitted ratiopharm’s s. 8 proceeding, claiming damages from Wyeth, to continue after it amalgamated with Teva.


Motion to amend judgment in SCC decision relating to sildenafil filed
  • Borden Ladner Gervais LLP
  • Canada
  • November 21 2012

Teva Canada Ltd.


Supreme Court of Canada considers patent sufficiency requirements
  • Borden Ladner Gervais LLP
  • Canada
  • November 8 2012

The Supreme Court issued its decision today in the much-anticipated patent case involving VIAGRA sildenafil.